Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

24 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Ablynx Articles

Briefs: Ablynx inks research deal with Spirogen; Solent Pharma debuts

25 February 2013

Algeta and Ablynx collaborate on tumor-targeting Nanobodies

22 November 2012

Merck & Co in Nanobody deal with Ablynx; J&J and Astellas join forces on RA

2 October 2012

Ablynx extends Nanobody deal with Boehringer

21 March 2012

Ablynx earns milestone from Merck Serono

13 December 2011

Merck Serono expands osteoarthritis collaboration with Ablynx

9 November 2011

Pfizer returns rights to TNF-alpha targeting nanobodies to Ablynx

7 November 2011

Pfizer Ph II study confirms efficacy of Ablynx' ozoralizumab in RA

20 May 2011

Batch of licensing deals announced by Merck KGaA, Novartis and Roche

13 July 2010

Ablynx gets 2 million-euro milestone from Boehringer Ingelheim Alzheimer’s collaboration; latter to unveil positive data on cancer drug

24 May 2010

Showing 1-10 of 10 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS